UroGen Pharma Ltd. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $89.0 million (+223.9% year over year). It usually reports 35–61 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 1, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Mar 2, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–61 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
89
+223.9%
|
-1
+95.6%
|
—
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
72
+199.2%
|
-14
+71.3%
|
—
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
51
+151.6%
|
-24
+46.2%
|
—
|
|
Mar 2, 2026
61 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
38
+54.0%
|
-26
+29.7%
|
—
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
27
+9.0%
|
-33
-40.9%
|
—
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
24
+10.8%
|
-50
-49.5%
|
—
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
20
+7.8%
|
-44
-35.8%
|
—
|
|
Mar 10, 2025
69 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
25
+4.4%
|
-38
-44.2%
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- URGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Ra'Anana, Israel
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1668243
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.